About Krystal Biotech, Inc.
https://www.krystalbio.comKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
CEO
Krish S. Krishnan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
IJR.AX
Weight:0.42%
Shares:1.53M
XAW.TO
Weight:0.01%
Shares:1.53M
VTS.AX
Weight:0.01%
Shares:819.55K
Summary
Showing Top 3 of 197
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Chardan Capital
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Cantor Fitzgerald
Overweight
Citigroup
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:4.34M
Value:$1.27B
BLACKROCK INC.
Shares:3.95M
Value:$1.15B
BLACKROCK, INC.
Shares:3.83M
Value:$1.12B
Summary
Showing Top 3 of 324
About Krystal Biotech, Inc.
https://www.krystalbio.comKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $97.8M ▲ | $50.76M ▲ | $79.36M ▲ | 81.15% ▲ | $2.74 ▲ | $49.58M ▲ |
| Q2-2025 | $96.04M ▲ | $49.57M ▲ | $38.33M ▲ | 39.91% ▼ | $1.33 ▲ | $40.85M ▲ |
| Q1-2025 | $88.18M ▼ | $46.98M ▲ | $35.73M ▼ | 40.52% ▼ | $1.24 ▼ | $37.81M ▼ |
| Q4-2024 | $91.14M ▲ | $44.81M ▼ | $45.48M ▲ | 49.9% ▲ | $1.58 ▲ | $42.93M ▲ |
| Q3-2024 | $83.84M | $54.72M | $27.18M | 32.42% | $0.95 | $36.46M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $731.07M ▲ | $1.24B ▲ | $102.22M ▲ | $1.14B ▲ |
| Q2-2025 | $681.99M ▲ | $1.14B ▲ | $97.75M ▲ | $1.04B ▲ |
| Q1-2025 | $616.85M ▲ | $1.07B ▲ | $89.74M ▼ | $984.67M ▲ |
| Q4-2024 | $597.52M ▲ | $1.06B ▲ | $109.46M ▲ | $946.38M ▲ |
| Q3-2024 | $588.32M | $982.32M | $96.47M | $885.85M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $79.36M ▲ | $39.66M ▼ | $-4.29M ▲ | $3.71M ▲ | $38.77M ▼ | $37.95M ▼ |
| Q2-2025 | $38.33M ▲ | $52.73M ▲ | $-10.53M ▲ | $1.8M ▲ | $45.06M ▲ | $50.83M ▲ |
| Q1-2025 | $35.73M ▼ | $30.97M ▼ | $-54.77M ▲ | $-12.47M ▼ | $-36.09M ▼ | $24.77M ▼ |
| Q4-2024 | $45.48M ▲ | $52.84M ▼ | $-83.78M ▼ | $2.43M ▼ | $-29.1M ▼ | $52.04M ▼ |
| Q3-2024 | $27.18M | $58.86M | $-34.33M | $3.37M | $28.18M | $57.81M |
CEO
Krish S. Krishnan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
IJR.AX
Weight:0.42%
Shares:1.53M
XAW.TO
Weight:0.01%
Shares:1.53M
VTS.AX
Weight:0.01%
Shares:819.55K
Summary
Showing Top 3 of 197
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Chardan Capital
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Cantor Fitzgerald
Overweight
Citigroup
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:4.34M
Value:$1.27B
BLACKROCK INC.
Shares:3.95M
Value:$1.15B
BLACKROCK, INC.
Shares:3.83M
Value:$1.12B
Summary
Showing Top 3 of 324